5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP) and kit for use with detecting cancer

• US 9,417,241 B2
• Filed: 03/10/2015
• Issued: 08/16/2016
• Est. Priority Date: 11/17/2000
• Status: Expired due to Term

• Current Assignee: BioAffinity Technologies, Inc.
• Original Assignee: BioAffinity Technologies, Inc.
• Inventors: Garwin, Jeffrey
• Primary Examiner(s): GITOMER, RALPH J
• Application Number:
  US14/643,194
• Publication Number:
  US 20150177245A1
• Time in Patent Office: 525 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/52 Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72
• CPC Class Codes: G01N 33/574 for cancer

Abstract

Presented is a kit containing TCPP for use in prognosing a patient'"'"'s response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient'"'"'s tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient'"'"'s tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

Claims

1. A kit for detection of dysplastic or cancerous cells in a sample, the kit comprising:

5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) in an aqueous alcoholic solution comprising between about 50% and about 90% alcohol, at a pH between about 8.5 and about 12.0, in a container and instructions for its use for detecting of abnormal precancerous or cancerous cells in a sample.

2. The kit of claim 1, further comprising one or more of:

a) components for collecting the sample of cells;

b) components for adhering the sample to a solid support;

c) control cell samples of known cancerous, dysplastic, metaplastic or normal condition; and

d) components for quantitating TCPP fluorescence.